deferasirox has been researched along with Cancer of Liver in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Akita, T; Jomen, W; Kohgo, Y; Ohtake, T; Osawa, Y; Suto, D; Yagi, H | 1 |
| Brissot, P; Cannie, I; Gaboriau, F; Gouffier, L; Leray, AM; Lescoat, G; Loréal, O; Ropert, M; Troadec, MB | 1 |
| Brissot, P; Chantrel-Groussard, K; Gaboriau, F; Lescoat, G; Nick, H; Pasdeloup, N | 1 |
3 other study(ies) available for deferasirox and Cancer of Liver
| Article | Year |
|---|---|
Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Topics: Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Line, Tumor; Deferasirox; Humans; Iron Chelating Agents; Liver Neoplasms; NF-kappa B; Sorafenib | 2022 |
Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
Topics: Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Deferasirox; Deferiprone; Dose-Response Relationship, Drug; Female; Ferritins; Hepatocytes; Humans; Iron; Iron Chelating Agents; Liver Neoplasms; Molecular Structure; Pyridones; Receptors, Transferrin; Triazoles | 2010 |
Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.
Topics: Animals; Apoptosis; Base Sequence; Benzoates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Deferasirox; Deferiprone; DNA Primers; DNA Replication; Humans; Iron Chelating Agents; Liver Neoplasms; Liver Neoplasms, Experimental; Polyamines; Pyridones; Rats; Triazoles | 2007 |